Glemanserin

Chemical compound From Wikipedia, the free encyclopedia

Glemanserin (INNTooltip International Nonproprietary Name; developmental code MDL-11,939) is a drug which acts as a potent and selective 5-HT2A receptor antagonist .[1][2] The first truly selective 5-HT2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated analogue.[3] Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinically for the treatment of generalized anxiety disorder and reached phase 3 trials for this use.[1][4] However, it was ultimately found to be ineffective and was not marketed.[1][4][5] The drug was also investigated for treatment of cardiac arrhythmias, but was not marketed for this use either.[1]

Other namesMDL-11,939; MDL-11939; MDL11939
Routes of
administrationOral[1]
Drug classSerotonin 5-HT2A receptor antagonist
ATC code
  • None
Quick facts Clinical data, Other names ...
Glemanserin
Clinical data
Other namesMDL-11,939; MDL-11939; MDL11939
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT2A receptor antagonist
ATC code
  • None
Identifiers
  • α-phenyl-1-(2-phenylethyl)-4-piperidine methanol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H25NO
Molar mass295.426 g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)C3CCN(CCc2ccccc2)CC3
  • InChI=1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2
  • Key:AXNGJCOYCMDPQG-UHFFFAOYSA-N
Close

See also

References

Related Articles

Wikiwand AI